Can a shot replace an IV for myeloma treatment?
NCT ID NCT04045795
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a drug combination (isatuximab, pomalidomide, and dexamethasone) in 56 patients with multiple myeloma that had returned or stopped responding to prior treatments. The main goal was to see if giving isatuximab as a shot under the skin works as well as giving it through an IV, and to check safety and side effects. Researchers also looked at how well the treatment controlled the cancer and how patients felt about the shot method.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
isatuximab (Sarclisa) plus pomalidomide and dexamethasone
What this could lead to
If successful, this could offer a new treatment option for patients with multiple myeloma that has returned or stopped responding to other therapies.
What could go wrong
This is an early-phase trial with only 56 participants, so results may not apply to all patients. Side effects from the drug combination are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Site Number : 8400002
Duarte, California, 91010, United States
-
Gabrail Cancer Center Site Number : 8400001
Canton, Ohio, 44718, United States
-
Investigational Site Number : 0360001
Wollongong, New South Wales, 2500, Australia
-
Investigational Site Number : 0360002
Blacktown, New South Wales, 2148, Australia
-
Investigational Site Number : 0360003
Richmond, Victoria, 3121, Australia
-
Investigational Site Number : 0360004
Fitzroy, Victoria, 3065, Australia
-
Investigational Site Number : 0560001
Leuven, 3000, Belgium
-
Investigational Site Number : 2500001
Nantes, 44093, France
-
Investigational Site Number : 2500002
Toulouse, 31059, France
-
Investigational Site Number : 3920001
Shibuya-ku, Tokyo, 150-8935, Japan
-
Investigational Site Number : 3920002
Okayama, Okayama-ken, 701-1192, Japan
-
Investigational Site Number : 7240001
Badalona, Catalunya [Cataluña], 08916, Spain
-
Investigational Site Number : 7240002
Santander, Cantabria, 39008, Spain
-
~Banner MD Anderson Cancer Center Site Number : 8400005
Gilbert, Arizona, 85234, United States